<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173746">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834106</url>
  </required_header>
  <id_info>
    <org_study_id>V501-041</org_study_id>
    <secondary_id>2009_532</secondary_id>
    <nct_id>NCT00834106</nct_id>
  </id_info>
  <brief_title>Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1
      VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and
      vaccine type-specific genital disease among Chinese females between the ages of 20 and 45.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Base Study V501-041 had a planned duration of 30 months. The study was extended to
      further evaluate the efficacy of Quadrivalent HPV (Type 6, 11, 16, 18) L1 VLP (qHPV) vaccine
      against Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), CIN 3, Adenocarcinoma In Situ
      (AIS), and/or cervical cancer. The total duration of the study extension is expected to be
      approximately 48 months, until the requisite number of primary efficacy endpoint cases (HPV
      16/18-related CIN 2 or worse) has accrued over the total study period (base study and
      extension).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2008</start_date>
  <completion_date type="Actual">September 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 11, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with persistent HPV 6, 11, 16 or 18 infection, or HPV 6/11/16/18-related genital disease</measure>
    <time_frame>Up to Month 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with CIN2, CIN3, AIS, and/or cervical cancer</measure>
    <time_frame>Up to Month 78</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3006</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>qHPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>qHPV</arm_group_label>
    <other_name>Gardasil â„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: placebo (unspecified)</intervention_name>
    <description>Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women between the ages of 20 and 45

          -  Have used effective contraception for 2 weeks prior to starting in the study

          -  Does not have a temperature within 24 hours before the first injection

        Exclusion Criteria:

          -  Prior history of genital warts

          -  More than 4 lifetime sexual partners

          -  Have undergone hysterectomy

          -  Have active cervical disease or history of cervical disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>January 30, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>April 25, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV 6/11/16/18 Infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
